CST, 45084S, PRAME Antibody

Polyclonal Antibody for studying PRAME. Validated for Western Blotting,Immunoprecipitation. Highly specific and rigorously validated in-house, PRAME Antibody (CST #45084) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunoprecipitation: 1:200 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunoprecipitation Specificity / Sensitivity PRAME Antibody recognizes endogenous levels of total PRAME protein. Species Reactivity: Human Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala167 of human PRAME protein. Antibodies are purified by protein A and peptide affinity chromatography. Background Cancer/testis antigens (CTAs) are a family of more than 100 proteins whose normal expression is largely restricted to immune privileged germ cells of the testis, ovary, and trophoblast cells of the placenta. Although most normal somatic tissues are void of CTA expression, due to epigenetic silencing of gene expression, their expression is upregulated in a wide variety of human solid and liquid tumors (1,2). As such, CTAs have garnered much attention as attractive targets for a variety of immunotherapy-based approaches to selectively attack tumors (3). PRAME (preferentially expressed antigen in melanoma) is a cancer/testis antigen not normally expressed in any tissues except testis, but is upregulated in tumors. PRAME is expressed in melanoma cells and is recognized by cytolytic T-cells (4). It is also upregulated in other diseases, such as synovial sarcoma (5), NSCLC (6), and breast cancer, where it is thought to contribute to tumorigenesis and metastasis (7). PRAME is also highly expressed in liquid tumors such as AML (8) and can be predictive of clinical outcome in some circumstances (9). PRAME and other cancer/testis antigens are currently being pursued as novel immunotherapy targets and diagnostic biomarkers (10). Alternate Names cancer/testis antigen 130; CT130; MAPE; Melanoma antigen preferentially expressed in tumors; OIP-4; OIP4; Opa-interacting protein 4; Opa-interacting protein OIP4; PRAME; PRAME nuclear receptor transcriptional regulator; preferentially expressed antigen in melanoma; Preferentially expressed antigen of melanoma Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 50 SOURCE: Rabbit